Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study
复制标题
DOI：
10.1016/j.ygyno.2008.08.020
复制
发表时间：
2008-12-01
影响因子：
4.7
通讯作者：
Farley, John H.
中科院分区：
文献类型：
--
作者：
Darcy, Kathleen M.;Brady, William E.;Farley, John H.
目标。妇科肿瘤学小组(GOG)对未经治疗的浸润性早晚期卵巢上皮性癌(EOC)患者的P53过度表达进行了详细分析。如果女性为翻译研究提供了肿瘤块，并参与了GOG-157，这是一项三比三(比)的随机第三阶段试验，那么她们就有资格参加这项研究。6个周期的紫杉醇+卡铂治疗高危早期卵巢癌，或GOG-111，环磷酰胺+顺铂与紫杉醇+顺铂在次优切除的晚期卵巢癌中的随机III期试验。用N-末端DO-7P53抗体检测主要正常和突变P53亚型的表达。P53过表达定义为：肿瘤细胞呈核染色。P53在GOG-157和GOG-111队列中的过度表达分别为51%(73/143)和66%(90/136)。在GOG157队列中，P53过表达与任何临床特征或总生存期(OS)无关，但与进展较差的无离子生存期(PFS)有关(LOGRANK检验：P=0.013；未校正COX模型：P=0.015)。在GOG-111队列中，P53的过度表达与GOG表现状态(p=0.018)和分级(p=0.003)有关，但与年龄、分期、细胞类型或肿瘤反应和疾病无关
Objective. The Gynecologic Oncology Group (GOG) performed a detailed analysis of p53 overexpression in previously-untreated women with invasive early or advanced stage epithelial ovarian cancer (EOC).Methods. Women were eligible for the study if they provided a tumor block for translational research and participated in either GOG-157, a randomized phase III trial of three versus (vs.) six cycles of paclitaxel+carboplatin in high-risk, early stage EOC, or GOG-111, a randomized phase III trial of cyclophosphamide+cisplatin vs. paclitaxel+cisplatin in suboptimally-resected, advanced stage EOC. The N-terminal DO-7 p53 antibody was used to examine the expression of the major normal and Mutant p53-isoforms. p53 overexpression was defined as >= 10%, tumor cells exhibiting nuclear staining.Results. p53 was overexpressed in 51% (73/143) and 66% (90/136) of cases in the GOG-157 and GOG-111 cohorts, respectively. In the GOG-157 cohort, p53 overexpression was not associated with any clinical characteristics or overall survival (OS) but was associated with worse progress ion-free survival (PFS) (logrank test: p=0.013; unadjusted Cox modeling: p=0.015). In the GOG-111 cohort, p53 overexpression was associated with GOG performance status (p=0.018) and grade (p=0.003), but not With age, stage, cell type or with tumor response and disease